X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
0.359
-0.012 (-3.21%)
Dec 3, 2024, 1:33 PM EST - Market open
X4 Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
| Revenue | 1.12 | - | - | - | 3 | - | Upgrade
|
| Gross Profit | 0.63 | - | - | - | 3 | - | Upgrade
|
| Selling, General & Admin | 56.3 | 35.51 | 27.02 | 24.7 | 20.94 | 17.64 | Upgrade
|
| Research & Development | 75.21 | 72.02 | 61.06 | 50.65 | 41.93 | 30.16 | Upgrade
|
| Operating Expenses | 131.51 | 107.52 | 88.08 | 75.35 | 62.87 | 47.8 | Upgrade
|
| Operating Income | -130.89 | -107.52 | -88.08 | -75.35 | -59.87 | -47.8 | Upgrade
|
| Interest Expense | -8.35 | -5.78 | -3.99 | -3.64 | -2.69 | -2.15 | Upgrade
|
| Interest & Investment Income | 5.95 | 4.58 | 0.22 | 0.01 | 0.27 | 1.2 | Upgrade
|
| Currency Exchange Gain (Loss) | 0 | 0 | -4.73 | - | -4.37 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 11.61 | 7.63 | 2.24 | 0.06 | 4.84 | 0.41 | Upgrade
|
| EBT Excluding Unusual Items | -121.67 | -101.09 | -94.35 | -78.92 | -61.82 | -48.34 | Upgrade
|
| Impairment of Goodwill | - | - | - | -9.76 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 105 | - | 0.51 | - | - | -3.9 | Upgrade
|
| Other Unusual Items | - | - | - | - | -0.16 | -0.57 | Upgrade
|
| Pretax Income | -16.67 | -101.09 | -93.84 | -88.68 | -61.98 | -52.81 | Upgrade
|
| Income Tax Expense | 0.09 | 0.08 | 0.03 | 0.02 | 0.15 | - | Upgrade
|
| Net Income | -16.76 | -101.17 | -93.87 | -88.7 | -62.13 | -52.81 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | 2.55 | 13.94 | - | 0.59 | Upgrade
|
| Net Income to Common | -16.76 | -101.17 | -96.41 | -102.64 | -62.13 | -53.4 | Upgrade
|
| Shares Outstanding (Basic) | 200 | 178 | 64 | 26 | 20 | 12 | Upgrade
|
| Shares Outstanding (Diluted) | 200 | 178 | 64 | 26 | 20 | 12 | Upgrade
|
| Shares Change (YoY) | 30.46% | 179.91% | 146.71% | 28.25% | 74.13% | 2411.98% | Upgrade
|
| EPS (Basic) | -0.08 | -0.57 | -1.52 | -3.99 | -3.09 | -4.63 | Upgrade
|
| EPS (Diluted) | -0.09 | -0.57 | -1.52 | -3.99 | -3.09 | -4.63 | Upgrade
|
| Free Cash Flow | -125.97 | -96.57 | -77.21 | -71.52 | -60.18 | -48.23 | Upgrade
|
| Free Cash Flow Per Share | -0.63 | -0.54 | -1.22 | -2.78 | -3.00 | -4.18 | Upgrade
|
| Gross Margin | 55.92% | - | - | - | 100.00% | - | Upgrade
|
| Operating Margin | -11654.94% | - | - | - | -1995.80% | - | Upgrade
|
| Profit Margin | -1492.34% | - | - | - | -2071.03% | - | Upgrade
|
| Free Cash Flow Margin | -11217.54% | - | - | - | -2006.00% | - | Upgrade
|
| EBITDA | -130.3 | -107.1 | -87.57 | -74.85 | -59.52 | -47.7 | Upgrade
|
| D&A For EBITDA | 0.59 | 0.42 | 0.51 | 0.5 | 0.35 | 0.1 | Upgrade
|
| EBIT | -130.89 | -107.52 | -88.08 | -75.35 | -59.87 | -47.8 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.